"Ergocalciferols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.
| Descriptor ID |
D004872
|
| MeSH Number(s) |
D04.210.500.247.222.474 D04.210.500.247.808.412 D04.210.500.812.768.462 D10.570.938.439
|
| Concept/Terms |
Vitamin D 2- Vitamin D 2
- Vitamin D2
- D2, Vitamin
- Ergocalciferol
|
Below are MeSH descriptors whose meaning is more general than "Ergocalciferols".
Below are MeSH descriptors whose meaning is more specific than "Ergocalciferols".
This graph shows the total number of publications written about "Ergocalciferols" by people in this website by year, and whether "Ergocalciferols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ergocalciferols" by people in Profiles.
-
Effect of Treating Vitamin D Deficiency in Uncontrolled Type 2 Diabetes: A Randomized, Placebo-Controlled Study. Am J Ther. 2019 Jul/Aug; 26(4):e441-e451.
-
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899.
-
Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017 Jul; 35(7):1039.e5-1039.e7.
-
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec; 21(6):416-24.
-
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jun; 73(9):970-8.
-
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011 Aug; 129(1):107-16.
-
Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol. 2008 Oct; 70(4):319-24.
-
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
-
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006 Feb; 47(2):263-76.
-
Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res. 2003 Sep 15; 9(11):4077-83.